Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cue Biopharma Inc (CUE)

Cue Biopharma Inc (CUE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 455,511
  • Shares Outstanding, K 22,994
  • Annual Sales, $ 1,140 K
  • Annual Income, $ -38,980 K
  • 60-Month Beta 1.66
  • Price/Sales 142.92
  • Price/Cash Flow N/A
  • Price/Book 17.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.51
  • Number of Estimates 1
  • High Estimate -0.51
  • Low Estimate -0.51
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +12.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.76 +26.02%
on 01/27/20
21.25 -12.47%
on 02/20/20
+3.39 (+22.29%)
since 01/24/20
3-Month
10.04 +85.26%
on 11/25/19
21.25 -12.47%
on 02/20/20
+8.57 (+85.44%)
since 11/22/19
52-Week
6.23 +198.56%
on 03/01/19
21.25 -12.47%
on 02/20/20
+12.37 (+198.56%)
since 02/22/19

Most Recent Stories

More News
Cue Biopharma's Therapeutic Immuno-STAT Platform to be Featured in Merck Presentation at Antigen-Specific Immune Tolerance Drug Development Summit

Presentation Provides Update on Immuno-STAT Platform Demonstrating Selective Modulation of Targeted T cells in Preclinical Models

MRK : 81.33 (-1.23%)
CUE : 18.60 (-6.11%)
Zacks.com featured highlights include: Farmers National, Independent Bank, First Financial Bankshares, HarborOne and Cue Biopharma

Zacks.com featured highlights include: Farmers National, Independent Bank, First Financial Bankshares, HarborOne and Cue Biopharma

FFIN : 33.17 (-2.50%)
IBCP : 21.40 (-2.01%)
FMNB : 15.90 (-0.93%)
HONE : 10.85 (-1.99%)
CUE : 18.60 (-6.11%)
5 Stocks to Make the Most of New Analyst Coverage

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

FFIN : 33.17 (-2.50%)
IBCP : 21.40 (-2.01%)
FMNB : 15.90 (-0.93%)
HONE : 10.85 (-1.99%)
CUE : 18.60 (-6.11%)
Cue Biopharma to Present at the Biomarkers Series UK

Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced...

CUE : 18.60 (-6.11%)
Zacks.com featured highlights include: Independent Bank, HarborOne, Horizon Technology Finance and Cue Biopharma

Zacks.com featured highlights include: Independent Bank, HarborOne, Horizon Technology Finance and Cue Biopharma

IBCP : 21.40 (-2.01%)
HRZN : 12.69 (-5.23%)
HONE : 10.85 (-1.99%)
CUE : 18.60 (-6.11%)
4 Stocks in Focus as New Analysts Show Interest

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

IBCP : 21.40 (-2.01%)
HRZN : 12.69 (-5.23%)
HONE : 10.85 (-1.99%)
CUE : 18.60 (-6.11%)
Cue Biopharma Announces Publication in Clinical Cancer Research of Preclinical and Translational Data Supporting the Therapeutic Potential of CUE-101 in HPV16-Related Malignancies

Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced...

FSNN : 0.0580 (-19.44%)
CUE : 18.60 (-6.11%)
Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari

Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.

NVS : 90.08 (-6.90%)
ALNY : 122.29 (-6.67%)
ALXN : 99.02 (-3.99%)
CUE : 18.60 (-6.11%)
Ultragenyx's Gene Therapy Positive in Genetic Disorder Study

Shares of Ultragenyx (RARE) rise 23.4% after releasing positive top-line data from the phase I/II study of its gene therapy candidate DTX301 for the treatment of OTC deficiency.

BAYRY : 19.0560 (-5.05%)
ALXN : 99.02 (-3.99%)
RARE : 57.02 (-3.99%)
CUE : 18.60 (-6.11%)
The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma

The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma

TNK : 12.90 (-9.47%)
EVER : 45.74 (-1.95%)
SAVA : 7.37 (-3.28%)
CUE : 18.60 (-6.11%)
FLGT : 16.86 (-11.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CUE with:

Business Summary

Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 20.50
1st Resistance Point 19.55
Last Price 18.60
1st Support Level 17.64
2nd Support Level 16.68

See More

52-Week High 21.25
Last Price 18.60
Fibonacci 61.8% 15.51
Fibonacci 50% 13.74
Fibonacci 38.2% 11.97
52-Week Low 6.23

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar